/1 and persistence of aggregation. By cytologic examination of the bone marrow an increase in cellularity was noted with 8% blasts and dysplastic features in all lineages with a prominent increase in megakaryocytes with apparent immature forms. In the peroxidase and Sudan Black staining 20% of the blasts stained positive with sporadic auer rods. Cytogenetic analysis showed a 46,XY,t(3;12)(q26;p13) [19] /46,XY [3] . A chronic myelomonocytic leukemia according to FAB classification (International Prognostic Score System: IPSS at diagnosis of 1.0; intermediate risk 1) with progression to RAEB-t with a unique t(3;12) was diagnosed. Hydroxyurea was started with only minor response. Splenectomy followed. He died of a cardiac event 18 months after the start of treatment.
Case 2: A 46-year-old woman with an unremarkable medical history was admitted to the hospital with bruising. On examination no abnormalities could be found except for some ecchymoses on her legs. Laboratory values revealed an Hb of 9.7 g/dl (n: 12.1-16.0), a leucocyte count of 4.5 × 10 9 /1 with 35% granulocytes, 46% lymphocytes, 7% monocytes, 10% bands, 1% metamyelocytes and 1% blasts. The platelet count was 36 × 10 9 /1 with several giant platelets. Blood chemical values were all normal. A cytological examination showed an increased cellularity with 23% blasts and strong dysplastic features most prominent in the myeloid lineage. Six percent of the blasts stained positive for peroxidase and Sudan Black. Cytogenetic analysis showed a 46,XX, t(3;12) (q2?5;p1?2) [20] . A diagnosis of RAEB-t (IPSS of 2.5; high risk) in progression to AML with an unique t(3;12) was diagnosed. She was treated with daunorubicin, cytosine arabinoside Ara-C and granulocyte-macrophage colony-stimulating factor (GM-CSF) according to an AML protocol without any response. She died 3 months after diagnosis.
Fluorescence in situ hybridization (FISH) analyses of metaphase spreads from short cultures of bone marrow cells were carried out according to standard protocols. The various probes are depicted in Figure 1a . A simultaneous whole chromosome paint of chromosomes 3 and 12 showed that chromosome 3 and chromosome 12 material is indeed exclusively present in the two normal and the two derivative chromosomes ( Figure 1b) . As a first step towards a fine-localization of the chromosome 12 breakpoint, bone marrow cells from both patients were hybridized with CEPH-YAC 964c10 containing the human genes ETV6 and PRB3. the der(12), and from the der(3) (Figure 1c) . Thus, the chromosome 12 breakpoint lies within the DNA segment that is covered by Y964c10, causing part of the human sequences of this YAC to be translocated to the derivative chromosome 3. The position of the chromosome 12 breakpoint relative to the coding region of this gene was assessed using a series of cosmids that span the entire gene and a segment downstream of it. Again, both patients gave identical results in all analyses, with cosmid C148b6 and cosmid C244e8 (see for origin of cosmids Ref. 1), flanking the breakpoint on either side. Exon 8 of ETV6, considered to be the last exon of this gene, lies in cosmid C148b6, approximately 30 kb upstream from the breakpoint. Thus, in neither of the two patients did the translocation appear to affect the coding region of ETV6, nor of any other known gene in this region. 1 In a similar way, we determined the chromosome 3 breakpoint for both patients. Based on the karyotype analysis we decided to focus on the MDS1-EVI1 gene region. In case 1, Y858c9 appeared to over-lap the chromosome 3 breakpoint (Figure 1d ). This YAC contains the genes EAP, MDS1 and EVI1. Two BACs (B328p24/B264d15) that map within Y858c9, and contain MDS1, hybridize with the normal chromosome 3 and with the der(12), indicating that the breakpoint lies centromeric to MDS1. The position of the breakpoint relative to EVI1 could not be elucidated. In case 2, the chromosome 3 breakpoint was flanked by Y846a1 and Y858c9, which positions the chromosome 3 breakpoint telomeric of MDS1, probably in the region between GLUT2 and EAP.
The expression of EVI1 was studied in both patients by RT-PCR as described previously.
2 In both patients an elevated level of EVI1 expression was observed as a clear band located at 254-281 bp. It is tempting to speculate that the translocation event has triggered the over-expression of EVI1 in the malignant cells. For case 2, one of the ETV6 genes is now positioned upstream of EVI1 on the derivate chromosome 3, with both genes in the same orientation. The positioning of this segment of chromosome 12 may trigger transcription of EVI1. A similar mechanism could be responsible for the EVI1 expression in case 1, assuming that the breakpoint lies telomeric to EVI1 in this case. A breakpoint centromeric to MDS1 was demonstrated in only one other case (Ref . 3; case 1) . For all other reported cases, the breakpoints on chromosome 3 were telomeric to EVI1 (Refs 4, 5; case 41, Ref. 6). However, EVI1 might also be expressed in cases without chromosomal abnormalities.
2 Therefore, the translocation could well be unrelated to the EVI1 expression and instead affect the transcription of other genes in the vicinity of the breakpoint.
The EVI1, MDS1, EAP, GLUT2 gene cluster, located on chromosome 3q26, is frequently associated with trilineage MDS with prominent dysmegakaryocytopoiesis, a short myelodysplastic phase preceding acute leukemia, and poor response to therapy. 5, 7 The 3q-abnormalities may activate aberrant expression of EVI1 which may be involved in disruption of erythroid and myeloid development through inhibition of GATA1 expression.
7-9 ETV6 appears to be involved in different translocations associated with myelodysplasia (MDS) and acute leukemia, sometimes resulting in chimaeric transcripts. 4, 10, 11 In t(12;22)(p13;q11) the MN1-ETV6 fusion protein may be involved in transformation of myeloid progenitor cells while the CBFA2-ETV6 transcript as a result of t(12;21)(p13;q22) may play a role in malignant transformation of lymphoid cells. A fusion of ETV6 with PDGFRB (platelet-derived growth factor receptor ␤-gene) in t(5;12) or fusion to a tyrosine kinase domain of ABL in t(9;12)(q34;p13) may alter tyrosine kinase activity of PDGFRB and ABL, respectively, affecting both lymphoid and myeloid lineages.
In conclusion, two patients with MDS with trilineage dysplasia and a unique t(3;12) are described, both expressing EVI1 in bone marrow cells which may be the result of the translocation since EVI1 is placed in the direct vicinity of ETV6. 
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